ALLO — Allogene Therapeutics, Inc.
Is ALLO overbought or oversold? Here is the current MarketMoodz read.
Allogene Therapeutics, Inc. (ALLO) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $0.81. The rating moved from Strong Oversold to Oversold on November 6, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$0.81
- Last changeMoved from Strong Oversold to Oversold on November 6, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Allogene Therapeutics, Inc. (ALLO) is an early‑stage allogeneic cell‑therapy developer with value tied to a small pipeline and upcoming clinical/regulatory milestones. The company’s lack of marketed products, capital‑intensive manufacturing profile and likely need for near‑term financing create downside pressure in a market that is rotating toward larger, defensive pharma names. Near‑term catalysts are binary and potential dilution, regulatory or manufacturing setbacks could be materially negative; upside would require positive clinical readouts, execution on manufacturing scale and a clear financing path.
Key factors
- Weak financial position / limited cash runway typical of early‑stage cell‑therapy developers
- No marketed products and high dependence on successful clinical readouts for value creation
- Complex, capital‑intensive manufacturing and scale challenges for allogeneic CAR‑T therapies
- Crowded competitive landscape (large pharma, other allogeneic and autologous CAR‑T developers)
- Macro flows favoring large‑cap defensive pharma over small biotech, reducing investor appetite
- High dilution risk from potential near‑term financing or convertible debt issuance
Risks
- Binary clinical outcomes: negative or ambiguous trial results could materially impair valuation
- Need for additional financing leading to significant shareholder dilution
- Regulatory setbacks or requests for additional data delaying programs
- Manufacturing, supply‑chain or quality issues that slow commercialization potential
- Strong competition from better‑funded incumbents and alternative immunotherapies
- Low liquidity and heightened share price volatility making short‑term moves abrupt
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for ALLO — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.